Indications for antifungal treatment in intensive care unit patients;Indicaciones del tratamiento antifúngico en pacientes ingresados en servicios de medicina intensiva

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 22, Issue 5, 2004, Pages 279-285

  Álvarez Lerma, Francisco ^a   Palomar, Mercedes ^b   León, Cristóbal ^c   Olaechea, Pedro ^d   Cerdá, Enrique ^e   Bermejo, Begoña ^f  

^a HOSPITAL DEL MAR   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^d HOSPITAL DE GALDAKAO   (Spain)

^e HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

^f Instituto de Investigación Sanitaria de Navarra   (Spain)

Author keywords

Amphotericin B; Antifungal drugs; Critically ill patient; Fluconazole; ICU; Use criteria

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; NYSTATIN;

ARTICLE; ARTIFICIAL VENTILATION; ASPERGILLUS; CANDIDA; CHEMOTHERAPY; CHRONIC LIVER DISEASE; CORTICOSTEROID THERAPY; CRITICAL ILLNESS; CRYPTOCOCCUS; DRUG INDICATION; ELECTIVE SURGERY; FUNGEMIA; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MYCOSIS; ORGAN TRANSPLANTATION; PRESCRIPTION; PROPHYLAXIS; RISK FACTOR; SEPSIS; SOLID TUMOR; URINARY TRACT INFECTION;

EID: 2942536125     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1157/13059821     Document Type: Article

References (37)

1. Vincent JL, Bihari DJ, Suter PM, Bruining HA, White J, Nicolas-Chanion MH, et al. The prevalence of nosocomial infection in intensive care unit in Europe. Results of the Europen study. JAMA 1995;274:639-44.
2. Insausti J. Consumo de antibióticos en Medicina Intensiva. En: Estudio Nacional de Vigilancia de Infección Nosocomial en UCI (ENVIN-UCI). Informe de la evolución de la incidencia y características de las infecciones nosocomiales adquiridas en Servicios de Medicina Intensiva (1994-2001). Madrid: Jarpyo Editores, 2002; p. 129-48.
3. Pizzo PA. Empirical therapy and prevention of infection in the immunocompromised host. En: Mandell GL, Douglas GR, Bennett JE, editors. Principles and practice of infectious diseases. New York: Churchill Livingstone, 2000; p. 3102-11.
4. Hughes WT, Armstrong D, Bodey GP, Brown AE, Edwards JE, Feld R, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin Infect Dis 1997;25:551-73.
5. Wade JC. Management of infection in patients with acute leukemia. Hematol Oncol Clin North Am 1993;7:293-315.
6. Roosen J, Frans E, Wilmer A, Knockaert DC, Bobbaers H. Comparison of premortem clinical diagnoses in critically ill patients and subsequent autopsy findings. Mayo Clin Proc 2000;75:562-7.
7. Ri MG, Konig J, Moecke HP, Gramm HJ, Barkow H, Kujath P, et al. Epidemiology of invasive mycosis in ICU patients: a prospective multicenter study in 435 non-neutropenic patients. Intensive Care Med 1997;23:317-25.
8. Nolla J, Sitges A, León C, Martínez L, León MA, Ibáñez P, et al. Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemeic antifungal therapy. Intensive Care Med 1997; 23:23-30.
9. Stoutenbeek CP, Van Saene HKF, Miranda DR, Zandstra DF, Langrehr D. The effect of oropharingeal decontamination using topical nonabsorbable antibiotics on the incidence of nosocomial respiratory tract infections in multiple trauma patients. J Trauma 1987;27:357-64.
10. D'Amico R, Pifferi S, Leonetti C, Torri V, Tinazzi A, Liberati A. Effectiveness of antibiotic prophylaxis in critically ill adults patients: a systematic review of randomized controlled trials. BMJ 1998;316:1275-85.
11. Vincent JL, Anaissie E, Bruining H, Demajo W, El-Ebiary M, Haber J, et al. Epidemiology, diagnosis and treatment of systemic Candida infections in surgical patients under intensive care. Intensive Care Med 1998;24:206-16.
12. Rex JH, Walsh TJ, Sobel JD, Filler SD, Papas PG, Dismukes WG, et al. Practice guidelines for the treatment of candidiasis. Clin Infect Dis 2000;30: 662-78.
13. Richardson MD, Kokki M. Therapeutic guidelines in systemic fungal infections. London: Current Medical Literature, 2001; p. 2-6.
14. Edwards JE (Conference chairman). International Conference for the Development of a Consensus on the management and Prevention of Severe Candidal Infections. Clin Infect Dis 1997;25:43-59.
15. Conferencia de Consenso de la Sociedad Española de Medicina Intensiva Crítica y Unidades Coronarias (SEMICYUC). Infecciones por Candida spp. en pacientes críticos. Med Intensiva 1999;23:3-7.
16. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: A severity of disease classification system. Crit Care Med 1985;13:818-29.
17. Center for Diseases Control 1993. Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adult. MMWR 1992; 41 (RR-17):1-19
18. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections. Am J Infect Control 1988;16:128-40.
19. Ascioglu S, Rex JH, De Pauw B, Bennet JE, Bille J, Crokaert F, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stam cell transplants: An international consensus. Clin Infect Dis 2002;34:7-14
20. Krueger WA, Lenhart FP, Neeser G, Ruckdeschel G, Schreckhase H, Eissner HJ, et al. Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients. A prospective, stratified, randomized, double-blind, placebo-controlled clinical trial. Am J Respir Criti Care Med 2002; 166:1029-37.
21. Fraser VJ, Jones M, Dunkel J, Storfer S, Medoff G, Dunagan WC. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis 1992;15:414-21.
22. Nolla J, León C, Jordá R, León MA, Pontes MJ, EPCAN Project Group. Risk factors for invasive candidiasis in non-neutropenic critically-ill patients. 40th ICAAC. Toronto (Canadá), 2000.
23. Blumberg HM, Jarvis WR, Soucie JM, Edwards JE, Patterson JE, Pfaller MA, et al. Risk factors for Candida bloodstream infections in surgical intensive care unit patients: The NEMIS prospective multicenter study. Clin Infect Dis 2001;33:177-86.
24. Álvarez Lerma F, Cerdà E, Jordá R, Palomar M, Bermejo B and ICU (EPIFUCI) Fungal Infection Study Group. Fungal isolates in critically ill patients admitted to intensive care units. Intensive Care Med 2000;26 (Suppl 1):234.
25. Kujath P, Lerch K, Kochendörfer P, Boos C. Comparative study of the efficacy of Fluconazole versus Amphotericin B/Flucytosine in surgical patients with systemic mycoses. Infection 1993;21:376-82.
26. Rex JH, Bennett JE, Sugar AM, Pappas PG, Van der Horst CM, Edwards JE, et al. A randomized trial comparing Fluconazole with Amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994;331:1325-30.
27. Abele-Horn M, Kopp A, Sternberg U, Ohly A, Dauber A, Russwurm W, et al. A randomized study comparing Fluconazole with Amphotericin B/5-Flucytosine for the treatment of systemic Candida infections in intensive care patients. Infection 1996;24:426-32.
28. Anaissie EJ, Darouiche RO, Abi-Said D, Uzun O, Mera J, Gentry LO, et al. Management of invasive candidal infections: Results of a propective, randomized, multicenter study of Fluconazole versus Amphotericin B and review of the literature. Clin Infect Dis 1996;23:964-72.
29. Phillips P, Shafran S, Garber G, Rotstein C, Smaill F, Fong I, et al. Multicenter randomized trial of Fluconazole versus Amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group. Eur J Clin Microbiol Infect Dis 1997;16:337-45.
30. Wingard JR, Kubilis P, Lee L, Yee G, White M, Walshe L, et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 1999;29:1402-7.
31. Bates DW, Su L, Yu DT, Chertow GM, Seger DL, Gomes DR, et al. Mortality and costs of acute renal falilure associated with amphotericin B therapy. Clin Infect Dis 2001;32:686-93.
32. Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised, controlled trial. BMJ 2001;322:579-82.
33. Álvarez-Lerma F, Nolla J, Palomar M, León MA. Intención de tratamiento de infecciones fúngicas en pacientes críticos ingresados en UCI. Enferm Infec Microbiol Clin 2003;21:83-8.
34. Hoffman HL, Rathbun RC. Review of safety and efficacy of voriconazole. Expert Opin Investig Drugs 2002;11:409-29.
35. Keating GM, Jarvis B. Caspofungin. Drugs 2001;61:1121-9.
36. León C, León MA, Nolla J, Jordá R, Álvarez F, León D. Colonización/infección fúngica en UCI. Situación actual. En: Aspectos actuales de la infección fúngica. Papel de caspofungina. Enferm Infecc Microbiol Clin 2002;(Supl 2):13-20.
37. Álvarez Lerma F, León C, Palomar M. Infección fúngica en pacientes ingresados en UCI. Enferm Infecc Microbiol Clin 2003;(Supl 1):27-33.